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evidence based approach to the treatment 
of community-associated methicillin-resistant 
Staphylococcus aureus
Abstract: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) 
infections have increased dramatically over the last two decades. The types of infections can 
range from complicated skin and skin structure infections (cSSSI) to pneumonia and endo-
carditis. Oral antimicrobial therapy, such as trimethoprim-sulfamethoxazole, clindamycin, 
long-acting tetracyclines, or linezolid may provide enhanced benefit to those with uncomplicated 
cutaneous lesions when used in conjunction with incision and drainage in an outpatient setting. 
However, resistance, susceptibilities, patient-specific circumstances, and adverse effects can 
impact a healthcare professional’s choice of antibiotics. In patients with complicated infections 
requiring hospitalization or parenteral treatment, vancomycin remains the drug of choice, even 
though increased resistance and decreased efficacy have crept into clinical practice. Linezolid, 
quinupristin/dalfopristin, daptomycin, and tigecycline are alternative intravenous agents for the 
treatment of CA-MRSA. Investigational agents such as dalbavancin, telavancin, oritivancin, 
iclaprim, ceftobiprole, ceftaroline, and others may expand our therapeutic armamentarium for 
the treatment of infections caused by CA-MRSA in the future.
Keywords: community-associated methicillin-resistant Staphylococcus aureus, CA-MRSA, 
complicated skin and skin structure infections, cSSSI, Panton-Valentine leukocidin, PVL, 
in vitro activity
Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) was first described in 1961 
soon after the introduction of methicillin, the first beta-lactamase resistant penicillin.1 
MRSA soon emerged as a common nosocomial organism infecting patients in hos-
pitals and intensive care units around the world.2 Prior to the 1990s, MRSA was 
almost exclusively a nosocomial organism. During the 1990s, MRSA began to infect 
patients with no known contact to healthcare organizations and who were otherwise 
healthy. These types of MRSA were noted to be genetically unique and soon began 
to be referred to as community-associated MRSA (CA-MRSA).3 Understanding this 
complex pathogen has now become a primary focus for many practitioners as illness 
related to CA-MRSA can be life-threatening. Despite major medical advances, MRSA 
continues to cause significant disease.
Epidemiology
CA-MRSA differs from healthcare-associated MRSA (HA-MRSA) genetically 
and epidemiologically. Methicillin resistance is mediated by the mecA gene which 
resides on the staphylococcal cassette chromosome mec (SCCmec). SCCmec 
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encodes for the penicillin-binding protein 2a (PBP2a) 
resulting in the inability of methicillin to bind to S. aureus.4 
CA-MRSA strains predominantly carry SCCmec type IV; 
however, SCCmec type V has also been identified in these 
strains.3 These SCCmec genes are generally smaller than 
those genes found in HA-MRSA strains allowing for 
more rapid spread. In addition, these genes only confer 
resistance to methicillin and other beta-lactams while 
maintaining susceptibility to narrow-spectrum antibiot-
ics such as tetracyclines, trimethoprim-sulfamethoxazole 
(TMP-SMX), and clindamycin. CA-MRSA, like HA-
MRSA, remains susceptible to vancomycin, linezolid, 
daptomycin, and quinupristin/dalfopristin (Q/D).3,5 One 
distinct feature of CA-MRSA is its ability to carry the 
gene encoding for Panton-Valentine leukocidin (PVL), a 
deadly exotoxin. This exotoxin is the key feature associ-
ated with CA-MRSA that causes necrotizing infections 
of the soft tissue as well as necrotizing pneumonias.2,6 
CA-MRSA did not originate from the hospital setting. 
Rather, it appears as though methicillin-susceptible 
S. aureus (MSSA) acquired the SCCmec gene producing 
a new genetic variant with two distinct clones occurring 
in the United States, USA300 and USA400. USA300 more 
frequently contains PVL genes and is now considered a 
major cause of necrotizing soft tissue infections.2,3 The 
Centers for Disease Control and Prevention (CDC) define 
CA-MRSA infections as those seen in people who meet 
the following criteria:7
–  Diagnosis of MRSA made in the outpatient setting or by a 
positive culture for MRSA within 48 hours of admission 
to the hospital.
–  No medical history of MRSA infection or colonization.
–  No medical history in the past year of:
  •  Hospitalization
  •    Admission to a nursing home, skilled nursing facility, 
or hospice
  •  Dialysis
  •  Surgery
–  No permanent indwelling catheters or medical devices 
that pass through the skin into the body.
One important development with CA-MRSA is the 
observation of these strains among patients in the healthcare 
setting. Because most patients acquire CA-MRSA from the 
community and because these infections can be quite serious, 
many may require hospitalization which can potentially transmit 
these strains to other inpatients.8 A review of 352 patients within 
the same institution with HA-MRSA found that CA-MRSA had 
become the most common cause of HA-MRSA. When MRSA 
strains were phenotyped, it was noted that the SCCmec IV gene 
increased from 17% to 56% in a 5-year period.9
Clinical presentation and risk 
factors
Skin and skin structures are the predominant sites of 
infection of CA-MRSA, furuncles being the most common 
type reported. CA-MRSA can also cause cellulitis, deep 
tissue abscesses, and in more serious cases, necrotizing 
fasciitis and osteomyelitis. CA-MRSA may be associated 
with localized necrosis caused by the PVL gene. Often, 
patients experience sudden onset of a raised red lesion 
with central necrosis resembling a spider bite.10 This can 
be confusing to both patients and physicians especially 
in areas of the United States where spider bites leading to 
cellulitis are uncommon. Presentations of this sort may be 
indicative of CA-MRSA infection as necrosis is a common 
feature of CA-MRSA both in skin and skin structure infec-
tions (SSSI) and lung infections. Pneumonia associated with 
PVL-producing CA-MRSA generally occurs as a necrotiz-
ing pneumonia with a high mortality rate.11 More cases of 
CA-MRSA necrotizing pneumonia have been seen in young, 
otherwise healthy children and adults.3 CA-MRSA necrotiz-
ing pneumonias are often seen following or concomitantly 
with an influenza-like illness. Patients often present with 
hemoptysis and a rapid onset of respiratory decompensa-
tion. In addition, patients appear septic with symptoms of 
hypotension, tachycardia, tachypnea, fever, and may often 
develop leukopenia.12
CA-MRSA has been reported to cause serious outbreaks 
of infections in certain populations including personnel in 
competitive team sports, Alaskan natives, Native Americans, 
correctional facility inmates, children, and military person-
nel.13 Transmission of CA-MRSA is predominantly through 
direct contact with an infected person. However, data from 
CA-MRSA outbreaks indicate that fomites, or inanimate 
objects, can also facilitate the spread of CA-MRSA.14 One 
notable incident occurred in 2003 when 8 MRSA infections 
developed in 5 professional football players. The MRSA 
clone was identified as a PVL-containing CA-MRSA which 
appeared to have been transmitted via close contact with 
infected abrasions and equipment.15
Risk factors for the acquisition of CA-MRSA are diffi-
cult to identify. It seems evident that close physical contact 
plays an important role; however, beyond that there are few 
well-designed studies that analyze risk factors.16 Risk fac-
tors that most healthcare professionals agree on are listed 
in Table 1.2,3,16,17Infection and Drug Resistance 2009:2 29
evidence based approach to the treatment of community-associated methicillin-resistant Staphylococcus aureus Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
In vitro activity
The assessment of in vitro activity of a given compound 
against select clinically significant pathogens has always been 
an early component in the development of new antimicrobials. 
Once the in vitro activity has been well defined, additional 
drug-specific data follow including basic pharmacokinetic 
parameters, human safety data, and ultimately, human outcome 
data. Specific to S. aureus, and more specifically MRSA, the 
differentiation into CA-MRSA and HA-MRSA subsets is a 
relatively new concept. Consequently, in vitro data for MRSA 
is not often subdivided into CA-MRSA or HA-MRSA. For 
the assessment of in vitro activity of various drugs against 
CA-MRSA, data are currently limited but accumulating. 
While it is unclear whether the genotypic identification of a 
given strain is clinically significant once susceptibility testing 
has been performed, it is clear that the susceptibility patterns 
differ based on the origin of the strain.
Use of the term CA-MRSA with regard to in vitro 
susceptibilities in contemporary literature generally refers 
to one of two issues. First, it may refer to strains which are 
consistent with the CDC definition as previously described.7 
Alternatively, the strain may have been genotyped and spe-
cifically identified to be a community-associated strain (ie, 
USA300, USA400, etc). For the purpose of this review, either 
determination has been considered sufficient to access in vitro 
activity. The in vitro activities of several antimicrobial agents 
have been evaluated against CA-MRSA and are summarized 
in Table 2. Included in this table are enteral and parenteral 
agents, both traditional and contemporary, which are com-
monly associated in the treatment of CA-MRSA infections.
Treatment options
Current guidelines recommend incision and drainage 
of uncomplicated-SSSI caused by CA-MRSA.18 Many 
patients can be treated with surgical drainage; however, 
antimicrobial therapy may provide additional benefits to the 
patient.19 Factors that may persuade a clinician to incorporate 
antimicrobial therapy into the treatment plan include: pres-
ence of cellulitis, swift enhancement of the SSSI, systemic 
illness, immunocompromised patient, age of the patient, 
abscess location that is difficult to access, and inappropri-
ate response to the initial incision and drainage.20 Multiple 
non-beta-lactam oral antibiotics are available for outpatient 
therapy including: TMP-SMX, clindamycin, long-acting 
tetracyclines, and linezolid.
Enteral treatment options
Trimethoprim-sulfamethoxazole  
(TMP-SMX)
TMP-SMX (Septra®; King Pharmaceuticals, Bristol, TN, 
USA) is not approved by the Food and Drug Administra-
tion (FDA) for the treatment of staphylococcal infections.21 
However, TMP-SMX has shown in vitro bactericidal proper-
ties against strains of CA-MRSA.22 The evidence to support 
the efficacy of TMP-SMX came from a randomized, control-
led clinical trial comparing it with vancomycin in intravenous 
drug abusers with various S. aureus infections, including 
bacteremia, endocarditis, osteomyelitis, and SSSI. Vanco-
mycin demonstrated superiority in the S. aureus treatment 
arm; however, the authors concluded that TMP-SMX is a 
viable treatment option in select cases of MRSA.23 In another 
study conducted in an ambulatory clinic, the increased use 
of TMP-SMX correlated with improved clinical outcomes 
in patients with SSSI.24 While data are lacking, TMP-SMX 
is widely used in clinical practice.
Clindamycin
Clindamycin (Cleocin®; Pfizer, Inc, New York, NY, USA) is 
another common antibiotic used to treat CA-MRSA.25 It has 
a potential protective effect against toxins, including the PVL 
toxin.26 There is a potential for resistance with high-inoculum 
infections via efflux or ribosomal alterations. A disk diffusion 
antibiotic assay (D-test) identifies inducible clindamycin 
Table 1 Risk factors for infection with community-associated 
methicillin-resistant Staphylococcus aureus (CA-MRSA)2,3,16,17
Children  2 years old
Children attending daycare centers
Injection drug users
Military personnel
Inmates
Homeless persons
Those in crowded living conditions
Household contact with a person known to be colonized and/or infected 
with MRSA
Men who have sex with men
HIv-infected persons
Athletes of contact sports
Adults  65 years old
Poor personal hygiene
History of colonization or recent infection with CA-MRSA
Recent influenza-like illness or pneumonia
African Americans
Pacific Islanders
Native AmericansInfection and Drug Resistance 2009:2 30
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Table 2 In vitro activity of select antimicrobial agents against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)
CA-MRSA
Antimicrobial agent No. of 
isolates
% susceptible MIC50  
(mg/mL)
MIC90  
(mg/mL)
MIC range  
(mg/mL)
Reference
Clindamycin 152 100 0.25 0.25 0.25 Sader et al 200876
157 97 na na na King et al 200689
127 96 na na na Huang et al 200688
348 93 na na na Naimi et al 200190
200 92 0.25 0.5 0.03 to 32 Tsuji et al 200791
23 91 na 0.13 0.06–64 Johnson et al 200649
1301 87 na na na Fridkin et al 200587
191 80.6 na na na Crum et al 200686
1989 34.2 8 8 0.06 to 8 Mendes et al 200845
Daptomycin 23 100 na 0.25 0.12–0.25 Johnson et al 200649
60 100 0.25 0.25 0.12–0.5 Saravolatz et al 200744
152 100 0.25 0.5 0.25–1 Sader et al 200876
200 100 0.5 1 0.13–2 Tsuji et al 200791
erythromycin 318 64 na na na Naimi et al 200190
185 20 na na na Crum et al 200686
1236 18 na na na Fridkin et al 200587
157 13 na na na King et al 200689
127 7 na na na Huang et al 200688
1989 5.7 8 8 0.06 to 8 Mendes et al 200845
200 4 16 16 0.13 to 16 Tsuji et al 200791
152 1.3 8 8 2 to 8 Sader et al 200876
23 0 na 64 2.0–64 Johnson et al 200649
Fluoroquinolones
Ciprofloxacin 325 93 na na na Naimi et al 200190
23 83 na 16 0.12–64 Johnson et al 200649
861 65 na na na Fridkin et al 200587
127 53 na na na Huang et al 200688
1989 15.1 4 4 0.03 to 4 Mendes et al 200845
Levofloxacin 152 92.8 0.25 0.5 0.12 to 4 Sader et al 200876
157 90 na na na King et al 200689
23 87 na 4 0.06–32 Johnson et al 200649
1989 15.5 4 4 0.06 to 4 Mendes et al 200845
200 12 16 16 0.125 to 16 Tsuji et al 200791
Moxifloxacin 23 96 na 1 0.03–4 Johnson et al 200649
Linezolid 23 100 na 2 2.0–2.0 Johnson et al 200649
200 100 2 4 0.24–4 Tsuji et al 200791
60 100 2 2 2 Saravolatz et al 200744
152 100 2 2 1–2.0 Sader et al 200876
1989 99.9 2 2 0.06–16 Mendes et al 200845
25 96 na na na Fridkin et al 200587
Quinupristin–dalfopristin 60 100 0.25 0.5 0.25–1 Saravolatz et al 200744
1989 99.9 0.5 1 0.25–2 Mendes et al 200845
Rifampin 23 100 na 0.03 0.03–0.03 Johnson et al 200649
127 100 na na na Huang et al 200688
(Continued)Infection and Drug Resistance 2009:2 31
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resistance in erythromycin-resistant, clindamycin-susceptible 
S. aureus isolates.27 While the rate of resistance to clindamy-
cin continues to be low in CA-MRSA, the frequency of 
inducible resistance is variable and unknown.28 Therefore, if 
confirmatory D-testing is not available, clindamycin should 
not be used to treat erythromycin-resistant CA-MRSA.
Tetracyclines
Doxycycline (Vibramycin®; Pfizer, Inc, New York, NY, 
USA) and minocycline (Minocin®; Wyeth Pharmaceuticals, 
Philadelphia, PA, USA) can also be effective in treating 
CA-MRSA SSSI.29,30 Although there are limited pub-
lished data, the long-acting tetracyclines appear to be 
good treatment options in most tetracycline-susceptible 
MRSA SSSI.31 Most laboratories in the United States test 
S. aureus for susceptibility to tetracycline (Sumycin®; 
Par Pharmaceuticals, Spring Valley, NY, USA) and not 
doxycycline or minocycline.32 The use of tetracycline as a 
surrogate may overestimate the prevalence of resistance to 
doxycycline or minocycline since there are two different 
Table 2 (Continued)
157 99 na na na King et al 200689
211 99 na na na Naimi et al 200190
887 98 na na na Fridkin et al 200587
1989 93.7 0.5 0.5 0.5–2 Mendes et al 200845
Tetracyclines
Doxycycline 200 86 0.5 8 0.06–16 Tsuji et al 200791
Minocycline 166 100 na na na Crum et al 200686
Tetracycline 249 95 na na na Naimi et al 200190
152 94.7 0.5 0.5 0.5–16 Sader et al 200876
23 91 na 0.5 0.13–32 Johnson et al 200649
1063 88 na na na Fridkin et al 200587
127 80 na na na Huang et al 200688
1989 9.1 2 4 2–8 Mendes et al 200845
Tigecycline 76 100 na na na McAlesse et al 200560
1989 98.2–100 0.12 0.5 0.12–0.5 Mendes et al 200845
Trimethoprim–sulfamethoxazole 23 100 na 0.06/1.19 0.03/0.59–0.5/9.5 Johnson et al 200649
152 100 0.25 0.25 0.25 Sader et al 200876
157 100 na na na King et al 200689
127 100 na na na Huang et al 200688
186 98.3 na na na Crum et al 200686
60 98 0.06/1.19 0.5/9.5 0.03/32–0.59/608 Saravolatz et al 200744
342 97 na na na Naimi et al 200190
1218 97 na na na Fridkin et al 200587
200 92 0.25 1 0.03–8 Tsuji et al 200791
1989 91.1 0.5 0.5 0.5–2 Mendes et al 200845
vancomycina 23 100 na 0.5 0.25–0.5 Johnson et al 200649
1989 100 1 1 0.25–4 Mendes et al 200845
60 100 0.5 0.5 0.25–1 Saravolatz et al 200744
152 100 1 1 0.5–2 Sader et al 200876
157 100 na na na King et al 200689
1345 100 na na na Fridkin et al 200587
127 100 na na na Huang et al 200688
343 100 na na na Naimi et al 200190
200 100 2 2 0.5–2 Tsuji et al 200791
aNot all vancomycin data are reflective of Clinical and Laboratory Standards Institute breakpoint changes made in 2006 specific to Staphylococcus aureus and may overestimate 
susceptibility.
Abbreviation: na, not available.Infection and Drug Resistance 2009:2 32
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genes that confer resistance, tetM and tetK. TetK confers 
resistance to tetracycline, while tetM confers resistance to 
all agents in the class. TetK has been the predominant gene 
associated with resistant isolates of MRSA in the community, 
which points towards the continued use and effectiveness of 
doxycycline and minocycline.33
Linezolid
Linezolid (Zyvox®; Pfizer, Inc, New York, NY, USA) may 
be a reasonable alternative following failure of treatment 
or allergic reactions.34 It is a bacteriostatic antimicrobial 
approved to treat MRSA complicated-SSSI (cSSSI). 
Controlled trials with linezolid versus vancomycin 
determined them to be comparable in treatment of MRSA 
cSSSI.35 Though resistance to linezolid is rare, the possibility 
of resistance has emerged with its increased use. 36 Similar 
to clindamycin, linezolid also suppresses the PVL toxin in 
CA-MRSA. This may prove beneficial in severe human 
infections with necrosis.37
Other antimicrobials
Rifampin (Rifadin®; Sanofi-Aventis, Bridgewater, NJ, USA) 
should never be used as a single agent for the treatment of 
MRSA SSSI because of the rapid resistance that can develop 
in S. aureus.38,39 Rifampin can be used in combination 
with other antimicrobial agents for potential eradication 
enhancement, but there is lack of evidence through studies, 
available for the benefit.40
Due to the relative ease of S. aureus in developing 
resistance with fluoroquinolone usage, they cannot be 
recommended for use in MRSA SSSI. The fluoroquinolo-
nes can cause chromosomal mutations in genes encoding 
the subunits of the drugs’ target enzymes, DNA gyrase and 
topoisomerase IV.41
Parenteral treatment options
Several parenteral agents are currently available for the 
treatment of serious infections caused by MRSA, regardless 
of the strain, which include vancomycin (or teicoplanin), 
Q/D, linezolid, daptomycin, and tigecycline (Table 4). 
While vancomycin has long been used for the treatment 
of MRSA, increasing resistance has begun to limit its use 
in contemporary clinical practice.85 Vancomycin has long 
been considered the “gold standard” for the treatment 
of MRSA, but recent reports of treatment failures are 
causing concern.42 Since the emergence of CA-MRSA, 
limited attention has been directed toward the efficacy 
of vancomycin due to the availability of multiple new 
compounds. Of the remaining parenteral agents, linezolid 
is the only agent with an oral formulation and has been 
previously discussed.
Quinupristin/dalfopristin (Q/D)
Q/D (Synercid®; Monarch Pharmaceuticals, Bristol, TN, 
USA) is a semisynthetic streptogramin antibiotic with 
a potent gram-positive spectrum of activity, including 
CA-MRSA.43–45 Prospective randomized controlled trials 
support its use for the treatment of bacteremia caused by 
vancomycin-resistant Enterococcus faecium and for cSSSI 
caused by MSSA or Streptococcus pyogenes.43,46,47 Despite 
previously demonstrated in vitro activity, Q/D lacks an 
indication in MRSA infections because this pathogen was 
not isolated in sufficient quantity to be evaluated. Historically 
the use of Q/D has been limited due to the high incidence of 
adverse reactions. Use is generally reserved for patients in 
whom conventional therapy is not tolerated or is otherwise 
contraindicated.
Daptomycin
Daptomycin (Cubicin®; Cubist Pharmaceuticals, Lexington, 
MA, USA) is a lipoglycopeptide antibiotic with a potent 
in vitro gram-positive spectrum of activity, specifically 
with rapid bactericidal action against MRSA.48 Additional 
in vitro data have also demonstrated the activity of dapto-
mycin against CA-MRSA.44,49 However, some data sug-
gest a relationship between decreased susceptibility of 
vancomycin to MRSA and a decreased susceptibility of 
daptomycin to MRSA.50–53 Randomized controlled trials 
support the use of daptomycin for the treatment of cSSSI 
due to susceptible strains of gram-positive pathogens, and 
for the treatment of bacteremia and right-sided endocarditis 
caused by S. aureus.54,55 MRSA was the pathogen identified 
at baseline in 9.3% (n = 40) of daptomycin-treated patients 
in the cSSSI trials and 37.4% (n = 45) in the right-sided 
endocarditis trial.54,55 The MRSA strains in these trials were 
not differentiated into HA-MRSA or CA-MRSA. Outcomes 
were found to be similar between daptomycin and compara-
tor for infections caused by MRSA. Prospective outcome 
data, however, are lacking for the treatment of CA-MRSA 
infections specifically. A retrospective evaluation assessed 
the use of daptomycin for the treatment of community-
phenotype-MRSA (CP-MRSA) infections, defined by the 
authors as MRSA with susceptibility to both clindamycin 
and TMP-SMX.56 All other phenotypes were classified by 
the authors as other-phenotype-MRSA (OP-MRSA). Of the 
352 patients included in this evaluation, 100 were classified Infection and Drug Resistance 2009:2 33
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as CP-MRSA and 252 as OP-MRSA. The CP-MRSA group 
tended to be younger with fewer underlying diseases. Success 
rate, time to clinical response, and duration of therapy were 
similar in both groups, prompting the authors to conclude 
that daptomycin was equally efficacious for the treatment of 
CP-MRSA or OP-MRSA infections in this select group of 
patients. However, these data cannot necessarily be extrapo-
lated to all patient populations.
Tigecycline
Tigecycline (Tygacil®; Wyeth Pharmaceuticals, Philadelphia, 
PA, USA), the first glycycline antibiotic, has a broad range 
of in vitro activity against most gram-positive (including 
MRSA), most gram-negative, and anaerobic bacteria.57 
Mendes and colleagues evaluated tigecycline against 1989 
human isolates of CA-MRSA collected from the SENTRY 
Antimicrobial Surveillance Program, 94.7% of which were 
PVL positive.45 Tigecycline was active against 98.2% of the 
strains tested, similar to the susceptibility rates for vancomy-
cin, teicoplanin, Q/D and linezolid. Randomized controlled 
clinical trials have demonstrated its safety and efficacy for 
the treatment of cSSSI and complicated intra-abdominal 
infections (cIAI).58,59 While MRSA has been included in 
the FDA approval for its association to cSSSI, it is lacking 
Table 3 Antimicrobials recommended for outpatient treatment of suspected methicillin-resistant (MRSA) skin and skin structure infections
Selection of empiric therapy should be guided by local susceptibility and modified based on results of culture and susceptibility testing. The duration of 
therapy for most SSSI is 7–10 days, but may vary depending upon the severity of infection and clinical response. Some infections may require a more 
prolonged treatment course.
Antimicrobial Adult dose Pediatric dose Considerations
Clindamycin1 300–450 mg PO QID 10–20 mg/kg PO per DAY 
divided into 3–4 doses per day;  
not to exceed adult dose.
See below1
Doxycycline or minocycline2 100 mg PO BID Do not use in children  8 years  
old.   Age  8 years old: 4 mg/kg 
PO per DAY divided BID;  
not to exceed adult dose.
Chelated by divalent cations. Separate 
from iron, calcium, and multivitamins. 
May make skin more sensitive to 
sunlight, sunburn may result. Do not 
use if pregnant or breastfeeding.
Linezolid3 600 mg PO BID Age  7 days–11 years old:  
10 mg/kg PO per DOSe given 
every 8 hours; not to exceed 
1200 mg daily. 
Age  12 years old: 600 mg  
PO BID.
Low-tyramine diet required. Avoid 
concominant MAO-I or SSRI agents 
due to potential for serotonin 
syndrome. Monitor CBC with 
prolonged courses (potential for 
leukopenia, thrombocytopenia). 
Monitor for peripheral neuropathy.
Rifampin4 300 mg PO BID 15–20 mg/kg PO per DAY 
divided BID; not to exceed  
600 mg daily.
NUMeROUS CYP450 drug–drug 
interactions. INR should be closely 
followed (for rapid decrease) in 
patients on warfarin. Causes bodily 
fluids (urine, sweat, etc.) to turn 
orange/red while on therapy.
Trimethoprim–sulfamethoxazole2 1–2 DS tablets (160 mg TMP/ 
800 mg SMX per tab) PO BID. 
May consider dose increase for 
morbidly obese patients  
(8–10 mg/kg TMP per DAY 
divided BID–TID, maximum dose 
2 DS tablets TID).
Base dose on TMP.   Age  
 2 months: 8–2 mg/kg TMP  
(40–60 mg/kg SMX) PO per DAY 
divided BID; not to exceed  
adult dose.
Dose adjustment required in 
renal dysfunction. Significant drug 
interaction with warfarin; INR 
should be closely followed for rapid 
increase. Avoid in patients with G6PD 
deficiency. May make skin more sensi-
tive to sunlight, sunburn may result.
1Clindamycin resistance is becoming increasingly prevalent. Pay close attention to the patient’s culture and sensitivity reports when considering Clindamycin use. Clindamycin 
should not be used if isolate is erythromycin resistant or if “inducible resistance” is present (D-test).
2For cellulitis of unknown cause where Group A Streptococcus may be a concern, clindamycin in combination with doxycycline/minocycline provides additional coverage for 
both organisms. Adjunctive clindamycin therapy may also be useful in toxigenic Staphylococci/Streptococci infections.
3Due to significant drug interactions and expense, infectious disease consultation is recommended when considering linezolid.
4Rifampin must always be used in combination with another antibiotic.
Notes: Outpatient use of fluoroquinolones or macrolides is NOT RECOMMENDED for routine treatment of MRSA. Resistance to fluoroquinolones can develop rapidly on therapy, 
so these agents should not be routinely used even if the isolate is reported to be susceptible. Consider a consultation with an infectious disease physician before prescribing.
Abbreviations: SSSI, skin and skin structure infections; MAO-I, monoamine oxidase inhibitor; SSRI, selective serotonin reuptake inhibitor; CBC, complete blood count; 
INR, international normalized ratio; G6PD, glucose-6-phosphate dehydrogenase.Infection and Drug Resistance 2009:2 34
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for cIAI due to a small sample size in the registration trials, 
similar to Q/D. A retrospective evaluation of the 173 MRSA 
isolates obtained from these phase III trials, 85% of which 
were from the cSSSI trial, found that 76 isolates had char-
acteristics consistent with known CA-MRSA on the basis 
of genotyping and the presence of both PVL-encoding locus 
and SCCmec type IV.60 All strains demonstrated in vitro 
susceptibility to tigecycline.
Drugs under investigation
Multiple antimicrobial agents with potent in vitro MRSA 
activity are currently in development. These agents are 
summarized in Table 5 with regard to drug name, route 
of administration, dose, indication for which it is under 
evaluation, and phase of development at this point of time. 
Drug classes currently in clinical use with additional drugs 
in development include glycopeptides, oxazolidinones, and 
a dihydrofolate reductase inhibitor. In addition, for the first 
time ever, beta-lactam antibiotics which possess MRSA 
activity, specifically new cephalosporins and carbapenems, 
are being developed.
Glycopeptides
Adding to vancomycin and teicoplanin of the glycopeptide 
drug class, dalbavancin, telavancin, and oritavancin are 
currently in the developmental stage. Dalbavancin is a 
semisynthetic lipoglycopeptide with a long half-life allowing 
for once-weekly dosing.61 Building on a successful phase II 
trial evaluating dalbavancin versus standard-of-care, a phase 
III trial evaluated dalbavancin versus linezolid for the treat-
ment of cSSSI.62,63 MRSA was identified in 51% of patients 
from whom a pathogen was isolated at baseline. Dalbavancin 
was well tolerated and efficacy was found to be noninferior. 
A phase II trial for bacteremia has yielded similar results.64 
In an in vitro evaluation of 329 pathogens associated with 
diabetic foot infections (DFIs), susceptibility to dalbavancin 
was compared with other antimicrobial agents.65 Of these 
329 pathogens, 60 were MRSA, with an estimated 50% sus-
pected CA-MRSA. Though this was not confirmed via pulse 
field gel electrophoresis (PFGE), 50% of the suspected 
CA-MRSA isolates were resistant to clindamycin with an 
MIC  8 µg/mL. The authors observed that dalbavancin 
was more active than vancomycin, daptomycin, and linezolid 
Table 4 Parenteral agents for the treatment of severe community-associated methicillin-resistant Staphylococcus aureus infections34,43,48,57,85
Drug Drug class Indication Dose (Intravenous) Considerations
Daptomycin Lipoglycopeptide cSSSI, bacteremia with right-sided  
infective endocarditis
4–6 mg/kg (actual body 
weight) every 24 hours
Dose adjust to every  
48 hours if CrCl  
 30 mL/min. Monitor CPK.
Linezolid Oxazolidinone uSSSI, cSSSI, CAP including  
concurrent bacteremia, NP
600 mg every 12 hours Low-tyramine diet 
required.   Avoid 
concominant MAO-I 
or SSRI agents due to 
potential for serotonin 
syndrome. Monitor CBC 
with prolonged courses 
(potential for leukopenia, 
thrombocytopenia). 
Monitor for peripheral 
neuropathy.
Quinupristin–dalfopristin Streptogramin Bacteremia, cSSSI 7.5 mg/kg (actual body 
weight) every 8–12 hours
Monitor LFTs. Use often 
limited by high inci-
dence of arthralgias and 
myalgias.
Tigecycline Glycylcycline cSSSI, cIAI 100 mg once, then  
50 mg every 12 hours
Does not achive optimal 
concentrations in 
blood or urine as highly 
distributed to the tissues.
vancomycin Glycopeptide Severe gram-positive  
infections
15 mg/kg every 12 hours Dose adjust in renal 
dysfunction. Monitor 
levels and SCr.
Abbreviations: cSSSI, complicated skin and skin structure infections; uSSSI, uncomplicated skin and skin structure infections; CAP, community-acquired pneumonia; NP, noso-
comial pneumonia; cIAI, complicated intra-abdominal infections; SCr, serum creatinine; LFTs, liver function tests; MAO-I, monoamine oxidase inhibitor; SSRI, selective serotonin 
reuptake inhibitor; CBC, complete blood count; CrCl, creatinine clearance; CPK, creatine phosphokinase.Infection and Drug Resistance 2009:2 35
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against MRSA. They concluded that the in vitro data, coupled 
with dalbavancin outcome data (versus linezolid for the treat-
ment of SSSI, including DFI), indicate that it may provide an 
advantage to patients with DFI in emergency departments, 
inpatient settings, and outpatient settings.
Telavancin, another lipoglycopeptide, possesses potent 
MRSA activity.66 An in vitro evaluation tested telavancin 
against 60 strains of CA-MRSA (as defined by the CDC).44 
Thirty-two (54%) of the 60 CA-MRSA strains were identified 
via PFGE to be the USA300 strain which harbors PVL genes. 
Telavancin demonstrated bactericidal activity against all 60 
CA-MRSA isolates, including all USA300 strains. A phase 
III study found telavancin to be safe and at least as effective 
as vancomycin for the treatment of cSSSI caused by gram-
positive organisms, including MRSA.67 Many of the MRSA 
isolates were SCCmec type IV and PVL positive.68
Oritavancin, another semisynthetic lipoglycopeptide 
with MRSA activity, has a long half-life allowing for less 
frequent dosing compared to contemporary glycopeptides.69 
Two phase III trials have been completed evaluating orita-
vancin versus comparator for the treatment of cSSSI.70,71 
Although these data are as yet unpublished, favorable results 
have been reported in abstract form and a new drug applica-
tion (NDA) was submitted to the FDA in early 2008 for the 
treatment of cSSSI. Additional data specific to CA-MRSA 
are lacking.
Oxazolidinones
Several oxazolidinones are currently in development. While 
multiple compounds are under investigation, most are in 
pre-clinical development stage and have not yet been named 
beyond their chemical number. AZD2563, for example, has 
demonstrated in vitro activity similar to linezolid against 
gram-positive pathogens, including MRSA.72 Additional oxa-
zolidinones have been evaluated by McKee and colleagues, 
but they are far from clinical development.73
Dihydrofolate reductase inhibitor
Iclaprim, a dihydrofolate reductase inhibitor similar to 
trimethoprim, is currently being evaluated as an intravenous 
formulation for the treatment of cSSSI in phase III trials. 
Table 5 Investigational agents with in vitro activity against methicillin-resistant Staphylococcus aureus
Drug Route Dose Indication under  
evaluation
Phase
Carbapenem
Multiple in early development na na na pre-clinical
Cephalosporin
Ceftopbiprole iv 500 mg every 12 hours cSSSI III
Ceftaroline iv 500 mg every 12 hours cSSSI III
Dihydrofolate reductase inhibitor
Iclaprim iv 0.8 mg/kg every  
24 hours
cSSSI III
iv na HAP (vAP and HCAP) II
iv to enteral 
switch
na cSSSI II
Oxazolidinone
Multiple in early development na na na pre-clinical
Synthetic glycopeptide
Dalbavancin iv 1000 mg on day 1, 
500 mg on day 8
cSSSI III
iv 1000 mg on day 1,  
500 mg on day 8
bloodstream II
Ortivancin iv 200 mg every  
24 hours
cSSSI III
Telavancin iv 10 mg/kg every  
24 hours
cSSSI III
Abbreviations: iv, intravenous; cSSSI, complicated skin and skinstructure infections; HAP, hospital-acquired pneumonia;   vAP, ventilator-acquired pneumonia; HCAP, healthcare-
associated pneumonia; na, not applicable.Infection and Drug Resistance 2009:2 36
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Positive outcomes have resulted in the submission of a 
NDA to the FDA., though the FDA has denied its approval. 
Iclaprim is currently under review in Europe and Canada. 
An intravenous-to-oral switch of iclaprim for the treatment 
of cSSSI is under evaluation in a phase II trial. Additionally, 
intravenous iclaprim for the treatment of hospital-acquired 
pneumonia, including both ventilator-associated pneumonia 
and healthcare-associated pneumonia is under evaluation in 
a phase III trial. Data specific to CA-MRSA are lacking.
Cephalosporins
Traditionally, cephalosporins have lacked activity against 
MRSA. Recently this changed with the introduction of 
ceftobiprole and ceftaroline which have a high affinity for 
PBP2a, and therefore exhibit good in vitro activity against 
MRSA, including CA-MRSA.74–76 When tested against 152 
strains of well-characterized CA-MRSA, the MIC50 and 
MIC90 for ceftobiprole were 0.5 and 0.5 µg/mL, respectively, 
with a range of 0.25–1 µg/mL. Breakpoints have not yet been 
established and consequently these results are up for interpre-
tation. Both ceftaroline and ceftobiprole are currently under 
investigation for safety and efficacy of the treatment of cSSSI; 
a NDA has since been filed with the FDA for ceftobiprole.
Carbapenems
Similar to the aforementioned cephalosporins, some inves-
tigational carbapenems have demonstrated in vitro activity 
against MRSA. Specifically, ME1036 has demonstrated 
activity against CA-MRSA.76 When tested against 152 strains 
of well-characterized CA-MRSA, the MIC50 and MIC90 
were 0.12 and 0.25 µg/mL, respectively, with a range of 
0.06–0.5 µg/mL. This, and other carbepenems with MRSA 
activity, are in the early stages of clinical development and 
may not reach market for several years. A review by Lo and 
colleagues has examined these agents in more detail.77
Complementary/alternative 
medicine
Tea tree oil (TTO) has been evaluated as a potential agent 
for both MRSA decolonization and treatment. It is available 
in many forms and is widely used in cosmetic preparations. 
Concentrations of TTO and product integrity are often vari-
able since it is not a regulated drug.
Several studies have evaluated the in vitro activity of TTO 
versus MRSA and many have shown promise, including one 
study indicating that TTO may be of benefit for eradication 
of MRSA biofilms.78 Translating in vitro data to clinical 
practice has yielded less consistent results. A study by Dryden 
and colleagues evaluated TTO for MRSA eradication in 
hospitalized patients.79 A standard 5-day regimen of mupirocin 
2% nasal ointment, chlorhexidine gluconate 4% skin cleanser 
and silver sulfadiazine 1% cream was compared to 10% tea 
tree cream and 5% tea tree body wash. Results indicated that 
mupirocin was significantly more effective at eradicating 
MRSA nasal carriage compared to TTO, 78% and 41% clear-
ance, respectively.
A study by McMahon and colleagues investigated 
whether the effect of sub-lethal challenge with TTO impacted 
the antibiotic resistance profiles of significant human patho-
gens.80 The authors note that TTO products often contain 
variable concentrations, and previously available data had 
not evaluated the impact of inappropriate or sublethal TTO 
concentrations. With respect to the MRSA strains used in 
the study, TTO caused an increased (2-fold or greater) MIC 
value for 7 out of 10 antibiotics tested.
In summary, before TTO is widely accepted as a standard-
of-care for treating MRSA or for MRSA decolonization, further 
clinical trial data are needed. If providers recommend TTO for 
treatment of CA-MRSA, it should be in conjunction with one of 
the traditional therapies previously discussed in this article.
Resistance
As discussed, most of the USA300 isolates are resistant to 
beta-lactam and macrolide antibiotics. Given that there are 
often other oral agents to treat most CA-MRSA strains, the 
question of development of resistance to these (doxycyline, 
minocycline, clindamycin, TMP-SMX) drugs is of concern. 
An epidemiologic study evaluated 123 USA300 isolates 
collected in an ambulatory health center in Boston, Massa-
chusetts.81 Of all the isolates, 83% had PFGE revealing either 
USA300–0114 (58% of total isolates) or USA300–0247 
(24% of total isolates). There were 12 multidrug-resistant 
(MDR) isolates reported, all of which contained the tetK 
and ermC genes. Of the USA300–0114 isolates (n = 73), 
72 (99%) were resistant to erythromycin, 36 (49%) were 
resistant to clindamycin and 10 (14%) were resistant to 
doxycycline. Two of the strains showed multidrug resist-
ance to erythromycin, levofloxacin, clindamycin and tetra-
cycline. Of the USA 300–0247 isolates (n = 29), 26 (90%) 
were resistant to erythromycin, 22 (76%) were resistant to 
clindamycin and 21 (72%) were resistant to tetracycline. 
Sixteen of the strains showed multidrug resistance to 
erythromycin, levofloxacin, clindamycin and tetracycline. 
Twelve isolates were tested for mupirocin susceptibility, 
and all were mupirocin resistant with MIC  128 µg/mL. 
The authors note that their resistance rates were considerably Infection and Drug Resistance 2009:2 37
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higher than other reported data as well as compared to the 
local health network.
A second retrospective study describes a USA300 strain 
that exhibits plasmid-mediated resistance to erythromycin, 
clindamycin and mupirocin.82 This retrospective study aimed 
to determine the incidence of an MDR MRSA clone (USA300) 
in San Francisco and risk factors associated with it. Based on 
an analysis from nine medical centers, the annual incidence 
of USA300 infection in San Francisco was estimated to be 
275 cases per 100 000 persons (95% CI, 256–295 cases per 
100 000 persons). With respect to USA300 infections contain-
ing a MDR conjugative plasmid, the annual incidence was 
26 per 100 000 persons (95% CI, 16–36 cases per 100 000 
persons). When eight zip codes were pooled, the incidence 
rose to 59 cases per 100 000 persons (95% CI, 36–82 cases 
per 100 000 persons). The other 18 zip codes evaluated only 
had incidence or 4 per 100 000 persons (95% CI, 0–8 cases 
per 100 000 persons). A single zip code had 25.7% of male 
same-sex couples, and incidence of MDR USA300 was 170 
cases per 100 000 persons (95% CI, 41–299 cases per 100 000 
persons). The authors conclude that men who have sex with 
men may be at higher risk for infection with MDR USA300. 
Data such as these reflect the need for astute monitoring of 
local epidemiologic patterns for CA-MRSA isolates.
Outpatient treatment approach
The treatment approach for CA-MRSA infections is 
variable based upon severity and site of infection. As dis-
cussed previously in this article, the majority of CA-MRSA 
infections are cutaneous infections and many may be 
managed on an outpatient basis. While the general consensus 
is that minor infections can be managed by incision and drain-
age (I&D) alone, many practitioners are opting to also treat 
with oral antimicrobials when MRSA diagnosis is confirmed 
by culture. A study by Moran and colleagues evaluated CA-
MRSA patients presenting to the Emergency Department.83 
Approximately 20% of patients underwent I&D alone, 10% 
were treated with antibiotics alone, and 66% received both 
I&D and antibiotic therapy. The 2005 Infectious Diseases 
Society of America Practice Guideline for the Diagnosis and 
Management of Skin and Soft-Tissue Infections recommends 
that if the infection involves inflammation of the surrounding 
tissue or has manifested in systemic symptoms, I&D with 
concomitant antimicrobial therapy.84 Figure 1 summarizes a 
Patient presents with 
signs/symptoms of skin 
infection
• May resemble insect 
or spider bite  
• Folliculitis, pustular lesions 
• Furuncle, carbuncle (boils) 
• Abscess (esp. with tissue 
necrosis)
• Cellulitis 
• Impetigo 
• Infected wound 
Is the lesion purulent (ie, are 
there any   of the following signs 
present)?
• Fluctuance (palpable fluid-
filled cavity), movable, 
compressible 
• Yellow, white or black center 
• Central point or “head” 
• Draining pus 
• Possible to aspirate pus 
with needle and syringe  
Possible cellulitis without 
abscess 
• Provide antimicrobial therapy 
with coverage for 
Streptococcus and/or other 
suspected pathogens 
• Maintain close follow-up 
• Consider adding coverage 
for MRSA (if not provided  
initially) if patient does not 
respond 
1. Drain the lesion 
2. Send wound drainage for 
culture and susceptibility 
testing 
3. Advise patient on wound care 
and hygiene 
4. Discuss follow-up plan with 
patient 
Yes
Yes
No
If systemic symptoms, severe local symptoms, immunosuppression, poor reliability for follow up, or failure to respond to I&D,
consider antimicrobial therapy with coverage for MRSA in addition to I&D. (See Table 3 for options)  
Risk Factors associated with CA-MRSA 
• Prior infection or contact with CA-MRSA
5 C’s: Crowding, Contact with skin,
Compromised skin, sharing
Contaminated personal care items, lack
of Cleanliness
Groups at risk: military recruits,
children, athletes, prisoners, intravenous
drug users         
•
•
Figure 1 Outpatient management of suspected community-associated methicillin-resistant Staphylococcus aureus skin and skin structure infections.
Adapted from Aurora Health Care MRSA Clinical Guidelines 2008. Kathryn Leonhardt, MD, MPH, editor.
Abbreviations: I&D, incision and drainage; MRSA, methicillin-resistant S. aureus; CA-MRSA, community-associated MRSA.Infection and Drug Resistance 2009:2 38
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possible treatment approach for the outpatient management 
of suspected CA-MRSA SSSI.
Conclusions
Although the changing epidemiology of MRSA has become 
better understood in recent years, the impact, both in and out 
of the hospital, still require further research and investigation. 
Understanding how to treat and prevent CA-MRSA is critical. 
Risk factors, optimal treatment, and infection prevention 
strategies need to be better defined and economic outcomes 
need to be measured. The most effective intervention appears 
to be prevention although this is one of the most difficult. 
As clinicians and patients become more educated about CA-
MRSA and its spread, common practices will likely require 
modification.
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